Provention Bio Inc (Nasdaq: PRVB), a clinical stage biopharmaceutical company involved in intercepting and preventing immune-mediated diseases, announced yesterday that it has named Sherron Kell, MD, MPH as its new senior vice president of Clinical Development.
In the new role, Dr Kell will lead the PRV-031 (teplizumab) program, including the oversight of the Phase three PROTECT study and clinical support of anticipated regulatory submissions, and will report to Dr Eleanor (Leni) Ramos, chief medical and operating officer.
Dr Kell most recently served as vice president at Impax Pharmaceuticals. Previously, she was senior director, Clinical R&D at Johnson & Johnson, and scientific director at Novartis Pharmaceuticals.
TiumBio files Clinical Trial Application to start Phase 1b TU7710 study
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Scancell initiates SCOPE trial's iSCIB1+ cohort
Valneva launches Phase 1 trial for next-generation Zika vaccine
argenx obtains VYVGART approval for primary immune thrombocytopenia in Japan
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval